BrainsWayBRSYF 70 Days Payable is 63.37 as of Mar. 2026, which is 16% below its 10-year median of 75.55. GuruFocus rates BRSYF with a GF Score™ of 70/100 and a GF Value™ of $6.24. The stock has 6 warning signs investors should review. Among 795 Medical Devices & Instruments companies, BrainsWay ranks worse than 57.48% on this metric.
BrainsWay's average Accounts Payable for the
three
months ended in Mar. 2026 was $2.68 Mil. BrainsWay's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $3.86 Mil.
Hence, BrainsWay's Days Payable for the
three
months ended in Mar. 2026 was 63.37.
The historical rank and industry rank for BrainsWay's Days Payable or its related term are showing as below:
BRSYF'
s Days Payable Range Over the Past 10 Years
Min: 41.16 Med: 75.55 Max: 197
Current: 60.76
During the past 13 years, BrainsWay's highest Days Payable was 197.00. The lowest was 41.16. And the median was 75.55.
BRSYF's Days Payable is ranked worse than 57.48% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs BRSYF: 60.76
BrainsWay's Days Payable
declined
from Mar. 2025 (77.53) to Mar. 2026 (63.37).
It may suggest that BrainsWayaccelerated paying its suppliers.
BrainsWay Days Payable Related Terms
BrainsWay Days Payable Historical Data
* Premium members only.
The historical data trend for BrainsWay's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, BrainsWay's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrainsWay Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BrainsWay's Days Payable distribution charts can be found below:
* The bar in red indicates where BrainsWay's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BrainsWay's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrainsWay (BRSYF) has a Days Payable of 63.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BrainsWay and its competitors. This is 16% below median its historical median of 75.55. Over the past decade, BrainsWay's Days Payable has ranged from 41.16 to 197.00. According to the industry distribution chart, BrainsWay ranks #457 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 57.5%.
Is BrainsWay's Days Payable too high?
BrainsWay's current Days Payable of 63.37 is 16% below median its 10-year median of 75.55. Over the past 10 years, this metric has ranged from a low of 41.16 to a high of 197.00. The Medical Devices & Instruments industry median Days Payable is 68.07. BrainsWay's value of 63.37 is 6.9% below this industry median. Based on the distribution chart, BrainsWay ranks #457 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, BrainsWay has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does BrainsWay's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, BrainsWay ranks #457 out of 795 companies for Days Payable. This places BrainsWay in the lower half of its industry. The industry median Days Payable is 68.07. BrainsWay's value of 63.37 is 6.9% below this benchmark. Historically, BrainsWay's own Days Payable has ranged from 41.16 to 197.00 over the past decade. While the company's 10-year median is 75.55 vs. the industry median of 68.07, BrainsWay has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrainsWay's current Days Payable of 63.37 is 6.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BrainsWay and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrainsWay's current Days Payable is 63.37, which is 16% below median its own 10-year median of 75.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrainsWay stock overvalued right now?
BrainsWay (BRSYF) has a current Days Payable of 63.37. The stock's GF Value™ is $6.24, compared to a current price of $13.55 — trading 117.1% above its estimated fair value. The current Days Payable is 63.37, which is 16% below median its 10-year median of 75.55 and 6.9% below the Medical Devices & Instruments industry median of 68.07. BrainsWay's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BrainsWay (BRSYF), the current Days Payable is 63.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BrainsWay (BRSYF) Overvalued in 2026?
Based on GuruFocus' analysis, BrainsWay stock appears to be overvalued.
The current stock price of $13.55 is trading 117.1% above its estimated GF Value™ of $6.24.
Key valuation signals for BRSYF:
Days Payable: 63.37 (16% below median its 10-year median of 75.55)
GF Value™: $6.24 vs. price of $13.55 (117.1% above fair value)
Industry Position: 6.9% below the Medical Devices & Instruments median (#457 of 795)
No single metric tells the full story. See the BRSYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
70GF Score
Get the complete analysis for BRSYF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRSYF has been successfully added to your 
